Research and Development

French software solutions provider for clinical trials Kayentis has formed a strategic committee comprising four industry veterans.  Accepting director Guillaume …

Amgen is pinning its hopes on investigational viral treatment T-VEC following promising results from a ‘landmark’ skin cancer study. People …

Eisai’s UK subsidiary has received a positive opinion from the European Medicines Agency for using Fycompa for the adjunctive treatment …

Sanofi has said Suresh Kumar is to join the French pharma giant on its executive committee and become executive vice …

A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …

Austrian-based clinical stage biopharma firm Nabriva Therapeutics has appointed Dr Elyse Seltzer as its chief medical officer. Seltzer assumes the role …

In May the UK went to the polls and elected a Conservative government to replace the coalition that had been …

Boehringer Ingelheim and Eureka Therapeutics have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.No …

US biopharma firm GW Pharmaceuticals has appointed Julian Gangolli as president of its North American division, and is also relocating its …

The battle for greater transparency in the pharma industry is to take another twist after a company lodged a legal …

Dr Marc Tessier-Lavigne is leaving Pfizer’s board of directors to work on the launch of Denali, a new biotech company …

This year’s American Society of Clinical Oncology (ASCO) conference has a strong focus on immunotherapy, as pharma ramps up its …

The Scottish government will increase its New Medicines Fund next year to double the amount of money available to fund …

Amgen has appointed Jonathan Graham as its senior vice president, general counsel and secretary who will take to his post in July. …

UK-based biotech Calchan has looked to Pfizer for appointing a new chief scientific officer in Zahid Ali. Ali has almost …